The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.00
Bid: 39.00
Ask: 41.00
Change: 0.00 (0.00%)
Spread: 2.00 (5.128%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 40.00
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

9 Sep 2015 07:00

RNS Number : 4675Y
Venture Life Group PLC
09 September 2015
 

Venture Life Group plc

 

("Venture Life" or "the Group")

 

Notice of Interim Results

 

 

Bracknell, UK - 9 September 2015: Venture Life Group plc (AIM: VLG), the international consumer products group addressing the self-care needs of the ageing population, will announce its Interim Results for the six months ended 30 June 2015 on Tuesday 29 September 2015.

 

- Ends -

 

For further information please contact:

 

Venture Life Group PLC

Jerry Randall, Chief Executive Officer

James Hunter, Chief Financial Officer

+44 (0) 1344 742870

Panmure Gordon (UK) Limited

Freddy Crossley / Duncan Monteith

+44 (0) 20 7886 2500

Corporate Finance

Tom Salvesen

Corporate Broking

Square1 Consulting

David Bick / Mark Longson

+44 (0) 20 7929 5599

 

 

Notes to editors

 

About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercializing products for the ageing population. The Group's product range and pipeline currently include food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

 

Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical device and cosmetic sectors. The Group's own branded products are currently sold or partnered in over 40 countries and currently include:

· food supplements to maintain brain function and memory;

· dermo-cosmetics for addressing the signs of skin ageing and hair loss, and

· medical devices for improving conditions such as minor aches and pains, dry eyes and itchy skin.

 

The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORDVLFBEKFEBBL
Date   Source Headline
24th Nov 20177:00 amRNSNew exclusive partner secured in Austrian market
23rd Nov 201711:14 amRNSUK Bond Network presentation
14th Nov 20177:00 amRNSVox Markets
30th Oct 20177:00 amRNSUltraDEX update
10th Oct 20177:00 amRNSHolding(s) in Company
2nd Oct 20177:00 amRNSFDA approval for the US market
21st Sep 20177:00 amRNSHalf-year Report
7th Sep 20177:00 amRNSDistribution partners and Lubatti China update
4th Sep 20177:00 amRNSNotice of Results
7th Aug 20174:24 pmRNSDirector/PDMR Shareholding
19th Jul 20177:00 amRNSDistribution partner for UltraDEX & patent update
12th Jul 20177:00 amRNSTrading update
23rd May 201710:59 amRNSResult of AGM
23rd May 20177:00 amRNSUltraDEX Patent Grants and Distribution Update
18th May 20177:00 amRNSTwo new CE Mark approvals
10th May 20179:00 amRNS'1000 Companies to Inspire Britain' 2017 report
4th May 20177:00 amRNSChange of Adviser
4th May 20177:00 amRNSGrant of Options
25th Apr 20177:00 amRNS2017 Long Term Incentive Plan and Grant of Options
29th Mar 20173:36 pmRNSUK Investor Show attendance
23rd Mar 20177:00 amRNSFinal Results
1st Mar 20177:00 amRNSDirectorate Change
1st Feb 20171:08 pmRNSHolding(s) in Company
31st Jan 20174:39 pmRNSInvestor Day presentation now available
26th Jan 20177:00 amRNSTrading update
20th Dec 20167:00 amRNSInvestor evening
29th Nov 20166:06 pmRNSHolding(s) in Company
28th Nov 20167:00 amRNSAppointment of Vox Markets
17th Nov 20167:00 amRNSInvestor evening
14th Nov 20167:00 amRNSTrading update
10th Nov 20167:00 amRNSDirectorate Change
10th Oct 20167:00 amRNSUltraDEX advertising launch
7th Oct 201612:10 pmRNSIssue of Equity
29th Sep 20167:00 amRNS2016 LTIP adopted & Grant of Options
21st Sep 20167:00 amRNSHalf-year Report
21st Sep 20167:00 amRNSAppointment of joint broker
7th Sep 20167:00 amRNSNotice of Results
29th Jul 20167:00 amRNSPre-close trading statement
22nd Jun 201612:35 pmRNSResult of AGM
14th Jun 201612:18 pmRNSDirector/PDMR Shareholding
17th May 20164:17 pmRNSDirector/PDMR Shareholding
9th May 20161:13 pmRNSDirector/PDMR Shareholding
9th May 20167:00 amRNSAnnual Financial Report
4th May 20167:00 amRNSFinal Results
3rd May 20167:00 amRNSFirst distribution agreements signed for UltraDEX
31st Mar 20167:00 amRNSDistribution Deals on Benecol 'once a day' Sachet
29th Mar 20167:02 amRNSNotice of Results
18th Mar 201611:04 amRNS'1000 Companies to Inspire Britain 2016' report
7th Mar 20167:00 amRNSCompletion of Acquisition
3rd Mar 20167:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.